Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

Summary

Article discusses AbbVie's strategic transformation following the patent expiration of Humira and the company's potential for growth driven by diversified pipeline. No specific catalyst, financial data, or clinical trial outcomes are provided.